Roche Wins First U.S. Approval for Breast Cancer Pill
The FDA approved Wilserdly (giredestrant) for use with Novartis’s Afinitor in advanced or metastatic breast cancer. Roche estimates peak annual sales could exceed 3 billion Swiss francs ($3.57 billion).
Roche has received FDA approval for its new oral breast cancer treatment, Wilserdly (giredestrant), indicated for use in combination with Novartis's Afinitor for patients with advanced or metastatic breast cancer. This marks the first regulatory approval for the drug, which Roche executives have identified as a potential future top-selling product for the company. The company has provided guidance estimating that the medication could generate over 3 billion Swiss francs ($3.57 billion) in annual sales at its peak. Roche is also currently seeking FDA approval for the drug to treat earlier phases of the disease, which would expand its eligible patient population.